CIPLA LTD vs PROCTER & GAMBLE HEALTH L

A side-by-side comparison of CIPLA LTD (CIPLA) and PROCTER & GAMBLE HEALTH L (PGHL) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, PROCTER & GAMBLE HEALTH L leads CIPLA vs PGHL on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability04
  • Growth11
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

PGHL takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.51
P/E ratio
29.20
3.42
P/B ratio
20.44
0.92%
Dividend yield
3.58%
₹48.02
EPS
₹196.94

Profitability

PGHL takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
62.29%
15.00%
Return on capital
84.00%
21.00%
EBITDA margin
32.43%
13.71%
Net margin
23.22%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
4.61%
10.88%
Profit CAGR (3Y)
12.60%

Size & financial health

CIPLA takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹9,590 Cr
₹28,163 Cr
Revenue
₹1,408 Cr
₹3,862 Cr
Net profit
₹327 Cr
0.00
Debt / equity
0.02
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
PROCTER & GAMBLE HEALTH L
  • + ["Company is almost debt free.", "Company has a good return on equity (ROE) track record: 3 Years ROE 42.6%", "Company has been maintaining a healthy dividend payout of 87.1%"]
  • ["Stock is trading at 17.9 times its book value", "The company has delivered a poor sales growth of 0.76% over past five years."]
CIPLA LTD full analysis PROCTER & GAMBLE HEALTH L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.